Early Onset of Neovascular Glaucoma After Intra-Arterial Thrombolysis for Central Retinal Artery Occlusion: A

Olga Furashova1, Joerg Thalwitzer2, Egbert Matthé3

  • 1Department of Ophthalmology, Klinikum Chemnitz gGmbH, Chemnitz, Germany.

Insights

Intra-arterial thrombolysis for central retinal artery occlusion (CRAO) may be associated with early neovascular glaucoma. Four of six patients developed this complication weeks after treatment for CRAO.

Area of Science:

  • Ophthalmology
  • Vascular Medicine
  • Neurology

Background:

  • Central retinal artery occlusion (CRAO) is a critical condition leading to vision loss.
  • Neovascular glaucoma (NVG) is a severe complication often associated with retinal vascular diseases.
  • Intra-arterial thrombolysis is a treatment option for acute CRAO.

Purpose of the Study:

  • To report on the occurrence of early-onset neovascular glaucoma in patients treated with intra-arterial thrombolysis for CRAO.
  • To investigate the potential association between CRAO treatment and subsequent NVG development.

Main Methods:

  • Retrospective analysis of medical records of six consecutive patients with acute CRAO.
  • All patients received intra-arterial thrombolysis within 4.5-6 hours of symptom onset.
  • Patients were monitored for complications, specifically neovascular glaucoma.

Main Results:

  • Six patients with acute CRAO were treated with intra-arterial thrombolysis.
  • None of the patients experienced visual improvement post-treatment.
  • Four out of six patients developed severe, painful neovascular glaucoma 4-7 weeks after CRAO onset.
  • Patients had no significant carotid stenosis or prior ophthalmic issues.

Conclusions:

  • Early-onset neovascular glaucoma can occur following intra-arterial thrombolysis for CRAO.
  • While CRAO itself may predispose to NVG, a possible association with intra-arterial thrombolysis warrants discussion.
  • Further research is needed to elucidate the exact relationship and underlying mechanisms.
Abstract

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
860
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
658
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
785